Revision 1

Store at -20C

#6889

BRM Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H Mk	Endogenous	200	Rabbit	#P51531	6595

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

BRM Antibody recognizes endogenous levels of total BRM protein. This antibody does not cross-react with BRG1 protein.

Species predicted to react based on 100% sequence homology

Dog

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly264 of human BRM protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

ATP-dependent chromatin remodeling complexes play an essential role in the regulation of various nuclear processes, such as gene expression, DNA replication, and repair (1,2). The SWI/SNF chromatin remodeling complex consists of more than 10 subunits with a single molecule of the ATPase catalytic subunit BRM or BRG1, but not both. The activities of these two subunits drive the disruption of histone-DNA contacts that lead to changes in accessibility of crucial regulatory elements within chromatin (2-5). The BRM/BRG1 containing SWI/SNF complexes are recruited to target promoters by transcription factors, such as nuclear receptors, p53, RB, and BRCA1 to regulate gene activation, cell growth, the cell cycle, and differentiation processes (1,6-9). BRM and BRG1 are also considered to be tumor suppressors and their expression levels are severely reduced in several cancer cell lines (10-13).

Background References

1. Ho, L. and Crabtree, G.R. (2010) *Nature* 463, 474-84.
2. Becker, P.B. and Hörz, W. (2002) *Annu Rev Biochem* 71, 247-73.
3. Eberharter, A. and Becker, P.B. (2004) *J Cell Sci* 117, 3707-11.
4. Bowman, G.D. (2010) *Curr Opin Struct Biol* 20, 73-81.
5. Gangaraju, V.K. and Bartholomew, B. (2007) *Mutat Res* 618, 3-17.
6. Lessard, J.A. and Crabtree, G.R. (2010) *Annu Rev Cell Dev Biol* 26, 503-32.
7. Morettini, S. et al. (2008) *Front Biosci* 13, 5522-32.
8. Wolf, I.M. et al. (2008) *J Cell Biochem* 104, 1580-6.
9. Simone, C. (2006) *J Cell Physiol* 207, 309-14.
10. Yamamichi, N. et al. (2005) *Oncogene* 24, 5471-81.
11. Reisman, D.N. et al. (2002) *Oncogene* 21, 1196-207.
12. Shen, H. et al. (2008) *Cancer Res* 68, 10154-62.
13. Weissman, B. and Knudsen, K.E. (2009) *Cancer Res* 69, 8223-30.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **Mk:** Monkey

Trademarks and Patents

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.